Patrick J. Haley Sells 52,636 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Exelixis Stock Up 0.3 %

Shares of NASDAQ EXEL opened at $37.65 on Friday. The business’s 50 day moving average is $34.42 and its two-hundred day moving average is $31.54. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $38.43. The firm has a market cap of $10.54 billion, a price-to-earnings ratio of 21.27, a PEG ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 765 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of Exelixis during the fourth quarter worth $32,000. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new position in Exelixis in the fourth quarter valued at $39,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on EXEL. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Barclays lifted their price objective on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Truist Financial boosted their price objective on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Piper Sandler lifted their price target on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Guggenheim reissued a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.